# First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

> **NCT01261767** · PHASE1 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 55 (actual)

## Conditions studied

- Inflammation
- Psoriasis

## Interventions

- **DRUG:** anti-IL-20
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01261767
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01261767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01261767, "First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01261767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*